This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: pioglitazone

Glitazones (thiazolidinediones)

July 2017 Br J Cardiol 2017;24:113–16 doi:http://doi.org/10.5837/bjc.2017.018 Online First

Glitazones (thiazolidinediones)

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text
In brief

August 2011 Br J Cardiol 2011;18:156–7

In brief

BJCardio Staff

Abstract

SAPIEN valve positive results Clinicians have achieved successful one-year outcomes in high-risk or inoperable patients undergoing transcatheter aortic valve replacement during the first two years since release of the valve (Sapien®, Edwards) commercially, according to results presented at the Euro PCR 2001 meeting in Paris, France. Despite high predicted mortality and multiple co-morbidities in many of these patients, survival at one year was 76% in the 1,038 patients treated as part of Cohort I (first year of commercialisation), and 77% in the 1,269 patients treated as part of Cohort II (second year of commercialisation).  Since November

| Full text
Drugs for diabetes: part 3 thiazolidinediones

February 2011 Br J Cardiol 2011;18:24-7

Drugs for diabetes: part 3 thiazolidinediones

David McGrane, Miles Fisher, Gerard A McKay

Abstract

Introduction During the past 10 to 15 years, numerous drugs have been introduced for the treatment of patients with type 2 diabetes to prevent the complications of poor glycaemic control. Two such oral drugs, rosiglitazone and pioglitazone, belong to the class of drugs called thiazolidinediones (TZDs), also known as glitazones. Both were licensed for use as monotherapy or in combination with other hypoglycaemic drugs. Through their actions on peroxisome proliferator-activated receptor (PPARγ), they improve hyperglycaemia and alter dyslipidaemia. It was hoped this would translate into cardiovascular benefits for patients taking them. Recent e

| Full text

March 2008 Br J Cardiol 2008;15:65-6

Rosiglitazone and pioglitazone – where do we go from here?

Sarah Jarvis

Abstract

The struggle to meet targets GPs are struggling to meet these targets, with only 56–59% of patients achieving HbA1c <7.5% in at least 50% of patients in 2004/5, and 59–62% of patients in 2005/6.6 While metformin has an excellent safety and efficacy record, and continues to be standard first-line therapy for all patients who can tolerate it, UKPDS has shown us that for most patients, multiple hypoglycaemic agents are necessary. Sulphonylureas are also well tried and tested, and relatively cheap, but carry the risk of weight gain and hypoglycaemia, especially with longer-acting versions such as chlorpropamide and glibenclamide. In additi

| Full text

November 2006 Br J Cardiol 2006;13:386-90

News from the Scientific Sessions 2006 of the American Heart Association

BJCardio editorial team

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now